Truist Securities Maintains Buy on Taysha Gene Therapies, Raises Price Target to $6
Portfolio Pulse from jenniferd'souza@benzinga.com
Truist Securities analyst Joon Lee maintains a 'Buy' rating on Taysha Gene Therapies (NASDAQ:TSHA) and raises the price target from $2 to $6.
August 15, 2023 | 2:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities maintains a 'Buy' rating on Taysha Gene Therapies and raises the price target from $2 to $6.
The 'Buy' rating maintained by Truist Securities and the increase in price target from $2 to $6 indicates a positive outlook for Taysha Gene Therapies. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100